Amgen And Astellas Announce Japan Alliance

                  Amgen And Astellas Announce Japan Alliance

Innovative Joint Venture to Address Unmet Medical Needs of Patients in Japan

PR Newswire

THOUSAND OAKS, Calif. and TOKYO, May 29, 2013

THOUSAND OAKS, Calif.and TOKYO, May 29, 2013 /PRNewswire/ --Amgen
(NASDAQ:AMGN), the world's largest independent biotechnology company, and
Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, "Astellas"), a leading
Tokyo-based global pharmaceutical company, today announced the companies have
entered into a strategic alliance to provide new medicines to help address
serious unmet medical needs of Japanese patients.

The alliance leverages the complementary capabilities of both companies
through an innovative business model that combines Amgen's pipeline candidates
with Astellas' deep knowledge of Japanese patient and physician needs,
long-term commercial and regulatory experience, and strong presence as a
leading company in Japan.

The first element of the alliance is a long-term collaboration between the two
companies that will focus on the co-development and co-commercialization in
Japan of five Amgen pipeline medicines. The five medicines, which include four
biologics and one small molecule, are focused on the treatment of
cardiovascular and bone diseases and cancer. The pipeline medicines range from
early to late stages of development in Japan, with the first potential
commercial launch expected as early as 2016.

The second element of the alliance is the establishment of a Tokyo-based joint
venture company through which the companies will work together to enable Amgen
to rapidly build on-the-ground capabilities in Japan. The joint venture will
operate under the name Amgen Astellas BioPharma KK and will be led by Eiichi
Takahashi, who will serve as general manager. Additional management roles will
be appointed by Amgen and Astellas. The joint venture will be staffed by
seconded employees from Astellas, transferred employees from Amgen and newly
hired employees. It is expected that the joint venture will start operations
on Oct. 1, 2013, and will become a wholly owned Amgen affiliate as soon as
2020 with the long-term collaboration continuing.

"Through this alliance, Amgen will work closely with Astellas to leverage its
extensive knowledge of the local market," said Robert A. Bradway, chairman and
chief executive officer at Amgen. "With Astellas' strong capabilities and
excellent reputation, this alliance will help accelerate development and
commercialization of Amgen medicines for patients in Japan. This alliance
reflects our long-term commitment to the Japan market and is an important step
in our global expansion efforts." 

"We look forward to entering this alliance with Amgen and believe it will
strengthen our pipeline to address unmet medical needs, as well as enable us
to obtain growth drivers," said Yoshihiko Hatanaka, president and CEO of
Astellas. "We will work closely with Amgen to build the joint venture, which
will provide innovative medicines to patients in Japan."

Goldman, Sachs & Co. is acting as financial advisor to Amgen in connection
with this transaction. Morrison & Foerster LLP served as external legal
counsel to Astellas.

Five Amgen Pipeline Medicines Included in the Amgen Astellas Alliance

Molecule     Lead Indication             Mode of Action      Development Stage
                                                             Global  Japan


AMG 145      Hyperlipidemia            Anti-PCSK-9 mAb     Phase 3 Phase 2




Romosozumab
             Osteoporosis                Anti-Sclerostin mAb Phase 3 Phase 2/3
(AMG 785)^1




Rilotumumab
             Gastric Cancer              Anti-HGF mAb        Phase 3 Phase 1
(AMG 102)




AMG 337      Gastric Cancer              MET inhibitor       Phase 1



             Acute Lymphoblastic
Blinatumomab Leukemia (ALL) and
             Non-Hodgkin's Lymphoma      Anti-CD19 BiTE^®    Phase 2
(AMG 103)    (NHL)



About Amgen

Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first
companies to realize the new science's promise by bringing safe, effective
medicines from lab to manufacturing plant to patient. Amgen therapeutics have
changed the practice of medicine, helping people around the world in the fight
against serious illnesses. With a deep and broad pipeline of potential new
medicines, Amgen remains committed to advancing science to dramatically
improve people's lives. For more information, visit www.amgen.com and follow
us on www.twitter.com/amgen.

About Astellas

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company
dedicated to improving the health of people around the world through the
provision of innovative and reliable pharmaceuticals. Astellas has
approximately 17,000 employees worldwide. The organization is committed to
becoming a global category leader in urology, immunology (including
transplantation) and infectious diseases, oncology, neuroscience and DM
complications and kidney diseases. For more information on Astellas Pharma
Inc., please visit the company website at www.astellas.com/en.

Amgen Forward-Looking Statements

This news release contains forward-looking statements that are based on
Amgen's current expectations and beliefs and are subject to a number of risks,
uncertainties and assumptions that could cause actual results to differ
materially from those described. All statements, other than statements of
historical fact, are statements that could be deemed forward-looking
statements, including estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and
prescriber patterns or practices, reimbursement activities and outcomes and
other such estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed below and more
fully described in the Securities and Exchange Commission (SEC) reports filed
by Amgen, including Amgen's most recent annual report on Form 10-K and any
subsequent periodic reports on Form 10-Q and Form 8-K. Please refer to
Amgen's most recent Form 10-K and any subsequent Forms 10-Q and 8-K for
additional information on the uncertainties and risk factors related to
Amgen's business. Unless otherwise noted, Amgen is providing this information
as of May 29, 2013, and expressly disclaims any duty to update information
contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ
materially from those Amgen projects. Discovery or identification of new
product candidates or development of new indications for existing products
cannot be guaranteed and movement from concept to product is uncertain;
consequently, there can be no guarantee that any particular product candidate
or development of a new indication for an existing product will be successful
and become a commercial product. Further, preclinical results do not
guarantee safe and effective performance of product candidates in humans. The
complexity of the human body cannot be perfectly, or sometimes, even
adequately modeled by computer or cell culture systems or animal models. The
length of time that it takes for Amgen to complete clinical trials and obtain
regulatory approval for product marketing has in the past varied and Amgen
expects similar variability in the future. Amgen develops product candidates
internally and through licensing collaborations, partnerships and joint
ventures. Product candidates that are derived from relationships may be
subject to disputes between the parties or may prove to be not as effective or
as safe as Amgen may have believed at the time of entering into such
relationship. Also, Amgen or others could identify safety, side effects or
manufacturing problems with Amgen's products after they are on the market.
Amgen's business may be impacted by government investigations, litigation and
product liability claims. If we fail to meet the compliance obligations in
the corporate integrity agreement between us and the U.S. government, we could
become subject to significant sanctions. Amgen depends on third parties for a
significant portion of its manufacturing capacity for the supply of certain of
its current and future products and limits on supply may constrain sales of
certain of its current products and product candidate development.

In addition, sales of Amgen's products are affected by the reimbursement
policies imposed by third-party payers, including governments, private
insurance plans and managed care providers and may be affected by regulatory,
clinical and guideline developments and domestic and international trends
toward managed care and healthcare cost containment as well as U.S.
legislation affecting pharmaceutical pricing and reimbursement. Government
and others' regulations and reimbursement policies may affect the development,
usage and pricing of Amgen's products. In addition, Amgen competes with other
companies with respect to some of its marketed products as well as for the
discovery and development of new products. Amgen believes that some of its
newer products, product candidates or new indications for existing products,
may face competition when and as they are approved and marketed. Amgen's
products may compete against products that have lower prices, established
reimbursement, superior performance, are easier to administer, or that are
otherwise competitive with its products. In addition, while Amgen routinely
obtains patents for its products and technology, the protection offered by its
patents and patent applications may be challenged, invalidated or circumvented
by its competitors and there can be no guarantee of Amgen's ability to obtain
or maintain patent protection for its products or product candidates. Amgen
cannot guarantee that it will be able to produce commercially successful
products or maintain the commercial success of its existing products. Amgen's
stock price may be affected by actual or perceived market opportunity,
competitive position, and success or failure of its products or product
candidates. Further, the discovery of significant problems with a product
similar to one of Amgen's products that implicate an entire class of products
could have a material adverse effect on sales of the affected products and on
Amgen's business and results of operations.

Contacts
Amgen, Thousand Oaks, Calif.
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)

Astellas Pharma Inc., Tokyo
Corporate Communications
Tel: +81-3-3244-3201
Fax: +81-3-5201-7473
http://www.astellas.com/en

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

(Logo: http://photos.prnewswire.com/prnh/20130529/LA21941LOGO)

^1 Developed in collaboration with UCB

SOURCE Amgen

Website: http://www.amgen.com